Can nicorandil treat angina pectoris effectively?

Nature Clinical Practice Cardiovascular Medicine

Volumn 2, Issue 4, 2005, Pages 186-187

  Thadani, Udho ^a  

^a University of Oklahoma Medical Center   (United States)

Author keywords

Angina pectoris; Nicorandil

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICORANDIL; NITRIC ACID DERIVATIVE; PLACEBO;

ANGINA PECTORIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DYSLIPIDEMIA; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SHORT SURVEY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 20444442795     PISSN: 17434297     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpcardio0159     Document Type: Short Survey

References (5)

1. Thadani U (2003) The pursuit of optimum outcomes in stable angina. Am J Cardiovasc Drugs 3 (Suppi 1): 11-20
2. Thadani U (2004) Current medical management of chronic stable angina. J Cardiovasc Pharmacol Ther 9 (Suppi 1): S11-S29
3. The IONA study group (2002) Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomized trial. Lancet 359: 1269-1275
4. Thadani U et al. (1994) Evaluation of antianginal and anti-ischemic efficacy of nicorandil: results of a multicenter study. J Am Coll Cardiol 23: 276A
5. Rajaratnam R et al. (1999) Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris. Am J Cardiol 83: 1120-1124